2024 annual financial data
Entrada Therapeutics 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -19.72%.
Operating income was 47,011,000 USD and net income was 65,626,000 USD.
Operating cash flow was -41,557,000 USD.
Get free Entrada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 210,782,000 USD
- Operating income
- 47,011,000 USD
- Net income
- 65,626,000 USD
- Operating cash flow
- -41,557,000 USD